Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 1;28(5):384-390.
doi: 10.1097/MOT.0000000000001094. Epub 2023 Aug 8.

Donor-derived infections in solid organ transplant recipients

Maddalena Peghin  1 , Paolo Antonio Grossi
Affiliations
Review

Donor-derived infections in solid organ transplant recipients

Maddalena Peghin et al. Curr Opin Organ Transplant. .

Abstract

Purpose of review: The potential for transmission of donor-derived infections (DDIs) is impossible to eliminate, but a thoughtful and systematic approach to donor evaluation can mitigate the risk. Prevention is a key issue and clinicians must maintain a high index of suspicion and remain vigilant in staying up to date on emerging infections. COVID-19 and Monkeypox have represented a new challenge for infectious disease screening and recommendations have been evolving, as knowledge in the field has grown. Additional considerations for pretransplant deceased donor screening include testing for neglected and endemic infectious diseases such as strongyloidiasis and HTLV 1/2. Molecular diagnostic tests have improved awareness on pathogenicity of mollicutes and fungi in the setting of DDIs. The aim of this review is to provide an update on the most recent literature on DDI with a special focus on these emerging hot topics.

Recent findings: Donor screening for uncommon pathogens must be guided by knowledge of changing epidemiology of infectious disease and availability of new diagnostic methods.

Summary: Appropriate screening, early recognition, timely reporting, close monitoring, and appropriate management are essential to help reducing the risk of emerging DDIs.

PubMed Disclaimer

Conflict of interest statement

P.A.G. has the following conflict of interest: Consulting fees from Merck, Sharp & Dohme, Gilead Sciences, Takeda, Allovir; member of speakers’ bureau for Merck, Sharp & Dohme, Gilead Sciences, Takeda, Astra-Zeneca; M.P. has no conflicts of interest to declare. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

Box 1
Box 1
no caption available
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kaul DR, Vece G, Blumberg E, et al. . Ten years of donor-derived disease: a report of the disease transmission advisory committee. Am J Transplant 2021; 21:689–702. - PubMed
    1. Loupy A, Aubert O, Reese PP, et al. . Organ procurement and transplantation during the COVID-19 pandemic. Lancet 2020; 395:e95–e96. - PMC - PubMed
    1. Kute VB, Fleetwood VA, Meshram HS, et al. . Use of organs from SARS-CoV-2 infected donors: is it safe? A contemporary review. Curr Transplant Rep 2021; 8:281–292. - PMC - PubMed
    1. Peghin M, Grossi PA. COVID-19 positive donor for solid organ transplantation. J Hepatol 2022; 77:1198–1204. - PMC - PubMed
    1. Kates OS, Fisher CE, Rakita RM, et al. . Use of SARS-CoV-2-infected deceased organ donors: should we always ‘just say no?’. Am J Transplant 2020; 20:1787–1794. - PMC - PubMed